Study of relationship between dose, LET and the risk of brain necrosis after proton therapy for skull base tumors - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Radiotherapy & Oncology Année : 2021

Study of relationship between dose, LET and the risk of brain necrosis after proton therapy for skull base tumors

Kamil Kisielewicz
  • Fonction : Auteur
Tomasz Skóra
  • Fonction : Auteur

Résumé

Purpose We investigated the relationship between RBE-weighted dose (DRBE) calculated with constant (cRBE) and variable RBE (vRBE), dose-averaged linear energy transfer (LETd) and the risk of radiographic changes in skull base patients treated with protons. Methods Clinical treatment plans of 45 patients were recalculated with Monte Carlo tool FRED. Radiographic changes (i.e. edema and/or necrosis) were identified by MRI. Dosimetric parameters for cRBE and vRBE were computed. Biological margin extension and voxel-based analysis were employed looking for association of DRBE(vRBE) and LETd with brain edema and/or necrosis. Results When using vRBE, Dmax in the brain was above the highest dose limits for 38% of patients, while such limit was never exceeded assuming cRBE. Similar values of Dmax were observed in necrotic regions, brain and temporal lobes. Most of the brain necrosis was in proximity to the PTV. The voxel-based analysis did not show evidence of an association with high LETd values. Conclusions When looking at standard dosimetric parameters, the higher dose associated with vRBE seems to be responsible for an enhanced risk of radiographic changes. However, as revealed by a voxel-based analysis, the large inter-patient variability hinders the identification of a clear effect for high LETd.

Dates et versions

hal-03346790 , version 1 (16-09-2021)

Identifiants

Citer

Magdalena Garbacz, Francesco Giuseppe Cordoni, Marco Durante, Jan Gajewski, Kamil Kisielewicz, et al.. Study of relationship between dose, LET and the risk of brain necrosis after proton therapy for skull base tumors. Radiotherapy & Oncology, 2021, 163, pp.143-149. ⟨10.1016/j.radonc.2021.08.015⟩. ⟨hal-03346790⟩
49 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More